OBJECTIVES: We wished to evaluate whether the presence of antibodies to HPV or to the HPV oncoproteins E6 and E7 or type of HPV DNA is related to prognosis among cervical cancer patients. METHODS: Blood samples were drawn from 313 patients with incident, untreated cervical cancer on admission to two hospitals in Sweden. Patients were followed from enrollment in 1984-1991 until death or up to June 1999. Clinical information was obtained from a review of medical records. Survival and cause of death were ascertained from both medical records and population-based cancer registries. The correlation of survival with antibodies to HPV16, to oncoproteins E6 and E7, and to type of HPV DNA was evaluated using multivariate Cox regression analysis, including stage, age, histology, and hospital in the model. RESULTS: Stage was the only significant prognostic factor influencing cervical cancer patient survival (OR = 3.62, 95% CI = 2.71-4.83). Age over 50 was associated with increased death rate among stage I-IIa patients (OR = 2.29, 95% CI = 1.12-4.68). Presence of antibodies to the oncoproteins E6 and E7 or to the HPV16 capsid or type of HPV DNA did not associate significantly with disease prognosis. CONCLUSIONS: Antibodies to HPV16 capsids and to oncoproteins E6 and E7 or type of HPV DNA do not appear to be useful as indicators of cervical cancer prognosis. (c) 2002 Elsevier Science (USA).
OBJECTIVES: We wished to evaluate whether the presence of antibodies to HPV or to the HPV oncoproteins E6 and E7 or type of HPV DNA is related to prognosis among cervical cancerpatients. METHODS: Blood samples were drawn from 313 patients with incident, untreated cervical cancer on admission to two hospitals in Sweden. Patients were followed from enrollment in 1984-1991 until death or up to June 1999. Clinical information was obtained from a review of medical records. Survival and cause of death were ascertained from both medical records and population-based cancer registries. The correlation of survival with antibodies to HPV16, to oncoproteins E6 and E7, and to type of HPV DNA was evaluated using multivariate Cox regression analysis, including stage, age, histology, and hospital in the model. RESULTS: Stage was the only significant prognostic factor influencing cervical cancerpatient survival (OR = 3.62, 95% CI = 2.71-4.83). Age over 50 was associated with increased death rate among stage I-IIa patients (OR = 2.29, 95% CI = 1.12-4.68). Presence of antibodies to the oncoproteins E6 and E7 or to the HPV16 capsid or type of HPV DNA did not associate significantly with disease prognosis. CONCLUSIONS: Antibodies to HPV16 capsids and to oncoproteins E6 and E7 or type of HPV DNA do not appear to be useful as indicators of cervical cancer prognosis. (c) 2002 Elsevier Science (USA).
Authors: Martha Luevano; Hans-Ulrich Bernard; Hugo A Barrera-Saldaña; Victor Trevino; Alejandro Garcia-Carranca; Luisa L Villa; Bradley J Monk; Xiaolin Tan; D Huw Davies; Phil L Felgner; Mina Kalantari Journal: Virology Date: 2010-06-15 Impact factor: 3.616
Authors: G J J Van Doornum; C M Korse; J C G M Buning-Kager; J M G Bonfrer; S Horenblas; B G Taal; J Dillner Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640
Authors: Zhen Dong; Renjian Hu; Yan Du; Li Tan; Lin Li; Juan Du; Longchang Bai; Yingkang Ma; Hongjuan Cui Journal: Front Immunol Date: 2021-01-08 Impact factor: 7.561
Authors: Aimée R Kreimer; Mattias Johansson; Tim Waterboer; Rudolf Kaaks; Jenny Chang-Claude; Dagmar Drogen; Anne Tjønneland; Kim Overvad; J Ramón Quirós; Carlos A González; Maria José Sánchez; Nerea Larrañaga; Carmen Navarro; Aurelio Barricarte; Ruth C Travis; Kay-Tee Khaw; Nick Wareham; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Petra H M Peeters; Salvatore Panico; Giovanna Masala; Sara Grioni; Rosario Tumino; Paolo Vineis; H Bas Bueno-de-Mesquita; Göran Laurell; Göran Hallmans; Jonas Manjer; Johanna Ekström; Guri Skeie; Eiliv Lund; Elisabete Weiderpass; Pietro Ferrari; Graham Byrnes; Isabelle Romieu; Elio Riboli; Allan Hildesheim; Heiner Boeing; Michael Pawlita; Paul Brennan Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Radwa Ewaisha; Gitika Panicker; Paul Maranian; Elizabeth R Unger; Karen S Anderson Journal: Theranostics Date: 2017-08-23 Impact factor: 11.556